Sartorius在2025年第一季度业绩公布后推动美国同行走高

Shares of Sartorius (OTCPK:SARTF) spiked in European trading on Wednesday after the German life sciences company recorded a strong start to 2025, with its Q1 results sending its U.S. peers higher in the premarket.

Notable gainers included Thermo Fisher Scientific (NYSE:TMO), Danaher Corporation (NYSE:DHR), Repligen (NASDAQ:RGEN), and Bio-Rad Laboratories (BIO).

Göttingen, Germany-based Sartorius (OTCPK:SARTF) reported €883M in revenue for the quarter with ~8% YoY growth, with its book-to-bill ratio, which reflects the ratio of order intake to sales revenue, standing well over one, according to the company.  

Sartorius (OTCPK:SARTF) said its Bioprocess Solutions division added €718M to the top line, while the Lab Products & Services division brought in €165M with ~11% YoY growth and ~4% YoY drop, respectively.

Meanwhile, the company’s underlying EBITDA jumped ~12% YoY to €263M thanks mainly to the revenue boost, improving EBITDA margin to 29.8% from 28.6% in the prior year period.

Underlying EBITDA at its Bioprocess Solutions expanded ~17% YoY to €226M due to favorable volume and product mix trends, while the Lab Products & Services division recorded €37M of underlying EBITDA.

The company expects its sales revenue growth to reach ~6% this year, thanks to 7% growth and 1% growth from the Bioprocess Solutions and Lab Products & Services divisions, respectively. Its underlying EBITDA margin for the year is estimated at 29% - 30%, with 31% - 32% of the margin attributed to the Bioprocess Solutions division.